HSF1 and NF-κB p65 participate in the process of exercise preconditioning attenuating pressure overload-induced

Tongyi Xu1, Ben Zhang2, Fan Yang3

  • 1Department of Cardiothoracic Surgery, No. 401 Hospital of PLA, Qingdao, China; Department of Cardiothoracic Surgery, Changhai Hospital, Second Military Medical University, Shanghai, China.

Insights

Exercise preconditioning (EP) effectively reduces cardiac hypertrophy in rats by upregulating heat shock proteins and inhibiting inflammatory pathways. This study demonstrates EP

Area of Science:

  • Cardiovascular Physiology
  • Exercise Science
  • Molecular Cardiology

Background:

  • Pathological cardiac hypertrophy, a common complication of hypertension and valve defects, leads to myocyte remodeling and cardiac dysfunction.
  • Exercise preconditioning (EP) is known to protect the heart against ischemia-reperfusion injury, but its role in pathological cardiac hypertrophy is understudied.

Purpose of the Study:

  • To investigate the effects of exercise preconditioning (EP) on pathological cardiac hypertrophy induced by transverse aortic constriction (TAC) in rats.
  • To elucidate the molecular mechanisms underlying the protective effects of EP in cardiac hypertrophy.

Main Methods:

  • Male Sprague-Dawley rats were divided into sham, TAC, EP + sham, and EP + TAC groups.
  • EP groups underwent 4 weeks of treadmill training before TAC surgery.
  • Cardiac function, morphology, histology, and protein expression (HSF1, HSP70, NF-κB p65, IL2) were assessed 8 weeks post-surgery.

Main Results:

  • TAC significantly increased hypertrophy indicators, which were effectively inhibited by EP treatment.
  • EP upregulated heat shock factor 1 (HSF1) and heat shock protein 70 (HSP70) expression, increasing nuclear HSF1.
  • EP inhibited nuclear translocation of the NF-κB p65 subunit and reduced myocardial IL2 levels.

Conclusions:

  • Exercise preconditioning (EP) significantly attenuates cardiac hypertrophic responses induced by TAC.
  • EP exerts a protective role by upregulating HSF1 and HSP70, activating HSF1, and subsequently inhibiting NF-κB p65 activation and IL2 expression.

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.5K
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.8K
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
10.8K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
1.3K
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
793
Exercise and Cardiovascular Response01:20

Exercise and Cardiovascular Response

Exercise significantly impacts cardiovascular response, which is crucial for understanding patient health and designing effective treatment plans.
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
6.2K